F Gary Toback

This inventor holds 18 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 1 EPO patent, primarily in Gastrointestinal Regeneration. Top assignees: The University of Chicago, Arch Development Corporation. Active years: 1992-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: F Gary Toback. Retrieved from https://idiyas.com/inventor/f-gary-toback

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 1)

% Patents Active = 50.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 2.3

ph-index = 5

Forward Citations = 73(Granted Patents)

Company Filing History:

10 out of 966

The University of Chicago

patents

8 out of 349

Arch Development Corporation

patents

Years Active: 1992-2014

Loading Chart...

Areas of Expertise:

Gastrokines

Peptides

Mucositis

Kidney Diseases

Growth Factors

Tissue Regeneration

Epithelial Cells

Autocrine Growth

Protein Production

Compositions

Detection Methods

Inhibitors

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8791068 - Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors (2014-07-29),

2. 8741838 - Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors (2014-06-03),

3. 8278269 - Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors (2012-10-02),

4. 8017576 - Methods and compositions to treat mucositis (2011-09-13),

5. 7910543 - Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors (2011-03-22),

6. 7629317 - Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors (2009-12-08),

7. 7557083 - Gastrokines and derived peptides including inhibitors (2009-07-07),

8. 7550438 - Methods for production of growth-promoting proteins and peptides for kidney epithelial cells (2009-06-23),

9. 7160864 - Methods for production of growth-promoting proteins and peptides for kidney epithelial cells (2007-01-09),

10. 6734289 - Gastrokines and derived peptides including inhibitors (2004-05-11),

11. 6534290 - Methods for production of growth-promoting proteins and peptides for kidney epithelial cells (2003-03-18),

12. 6482934 - Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells (2002-11-19),

13. 6096706 - Growth-promoting proteins and peptides for kidney epithelial cells (2000-08-01),

14. 6043216 - Methods and composition for detecting and treating kidney diseases (2000-03-28),

15. 5821218 - Regeneration of kidney tissue and use of autocrine growth factors (1998-10-13),

Title: The Innovative Journey of F Gary Toback: Pioneering Gastro-Intestinal Therapies

Introduction:

F Gary Toback, a talented inventor hailing from Chicago, IL, has left a significant mark in the realm of medical innovations with a remarkable 18 patents under his belt. His groundbreaking work in gastro-intestinal research has paved the way for novel therapies and advancements in the field.

Latest Patents:

One of Toback's latest patents revolves around the control of growth and repair of gastro-intestinal tissues by introducing a novel group of gastrokines known as Gastric Antrum Mucosal Protein. This includes the characterization of AMP-18, a key member of the group with vast implications in cellular growth factors. The derived peptides not only aid in tissue repair but also exhibit inhibitory properties, holding promise for treating conditions such as inflammatory bowel disease, mucositis, and gastric ulcers.

Career Highlights:

Throughout his career, Toback has been associated with esteemed institutions such as the University of Chicago and the Arch Development Corporation. His dedication to pushing the boundaries of medical science and his commitment to improving patient outcomes have been evident in his prolific patent portfolio.

Collaborations:

Toback has collaborated closely with accomplished peers in the field, including Margaret M Walsh-Reitz and Terence E Martin. Together, they have contributed to the advancement of gastro-intestinal research and the development of innovative therapeutic solutions.

Conclusion:

In conclusion, F Gary Toback's innovative spirit and unwavering dedication to medical advancements have established him as a trailblazer in the field of gastro-intestinal research. His patents not only showcase his ingenuity but also underscore his commitment to improving healthcare outcomes for patients worldwide.

Profile summary based on public USPTO records.